首页> 外文期刊>Journal of Inorganic Biochemistry: An Interdisciplinary Journal >A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV)
【24h】

A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV)

机译:一种新型的口服活性抗糖尿病钒化合物-双(α-呋喃甲酸)氧钒(IV)

获取原文
获取原文并翻译 | 示例
           

摘要

Bis(alpha-furancarboxylato)oxovanadium(IV)--a new orally active antidiabetic vanadyl complex has been synthesized, characterized, and tested for bioactivity as insulin-enhancing agents. The complex was administered intragastrically to both normal and STZ-diabetic rats for 4 weeks. The results show that the complex at a dose of 10.0 and 20.0 mg V kg(-1), could significantly lower the blood glucose level rats and ameliorated impaired glucose tolerance in STZ-diabetic, but not in normal rats. It was suggested that the complex exerted an antidiabetic effect in STZ-diabetic rats, which maybe was related to increasing the sensitivity to insulin.
机译:双(α-呋喃羧基)氧钒(IV)-一种新的口服活性抗糖尿病钒钒复合物已被合成,表征并测试了其作为胰岛素增强剂的生物活性。将该复合物胃内给药于正常和STZ-糖尿病大鼠,持续4周。结果表明,该复合物的剂量为10.0和20.0 mg V kg(-1),可以显着降低STZ糖尿病大鼠的血糖水平,改善其糖耐量的降低,而正常大鼠则不然。提示该复合物在STZ-糖尿病大鼠中具有抗糖尿病作用,这可能与增加对胰岛素的敏感性有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号